Alzheimer's Disease Stem Cells Multiple Infusions

Inclusion criteria

All subjects enrolled in this trial must:

• Provide written informed consent
• Male or female subjects aged 50-85 years at time of signing Informed Consent
• Mini-Mental State Examination (MMSE) between 20-26
• Amyloid PET scan or CSF Aß1-42 positive for the presence of amyloid
• Meet criteria for either Alzheimer's Disease or probable Alzheimer's Disease (AD) according to National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINDCDS/ARDRA)
• Subjects, if taking cholinesterase inhibitor medications (donepezil, rivastigmine (oral or transdermal) or galantamine), are required to have been taking them on a stable dose for at least 3 months prior to Baseline Visit These medicines are not required
• Subjects already taking memantine will not have an effect in the inclusion/exclusion criteria.
• Have a study partner
• No clinically significant abnormal screening laboratory values, as determined by the investigator
• Women must be postmenopausal, surgically sterile, or having infertility. A postmenopausal woman is defined as either having an intact uterus with at least 12 months of spontaneous amenorrhea or a diagnosis of menopause, defined as an Follicular Stimulating Hormone (FSH) level of > 25 IU/L

Exclusion criteria

All subjects enrolled must not have:

• Dementia other than AD
• A negative Amyloid PET scan
• Other neurodegenerative disease
• Significant psychiatric illness (e.g., uncontrolled major depression, schizophrenia, bipolar affective disorder)
• History of seizures
• Contraindication for Magnetic Resonance Imaging (MRI)
• History of malignancy, except:

• > 5 years in remission prior to screening
• Be excised or treated basal cell, squamous carcinoma or melanoma in situ
• Prostate cancer in situ
• Cervical carcinoma in situ
• Uncontrolled medical conditions

• Hypertension
• Diabetes
• Unstable angina or history of Myocardial Infarction (MI) within 1 year prior to screening
• History of alcohol or drug use disorder (except tobacco use disorder) within 2 years before the screening visit
• Brain MRI at screening that shows evidence of findings incompatible with a diagnosis of Alzheimer's disease. Volumetric MRI scans done within 6 months prior to ICF signature will be accepted if completed locally.
• History of bleeding disorder
• History of or positive results for Human Immunodeficiency Virus (HIV)
• History of or positive results for Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV)
• Hypersensitivity to dimethyl sulfoxide (DMSO)
• Inability to perform any of the assessments required for endpoint analysis
• Currently receiving (or received within four weeks of screening) experimental agents for the treatment of AD or enrolled in clinical trials in the prior 3 months
• Be a transplant recipient, or on active listing (or expected future listing) for transplant of any organ.
• Any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study.